Clinical Trials · NCT03973047
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Enrollment
- 228
- Start date
- Jun 2019
- Locations
- 1 site, United States
- Primary endpoint
- Incidence of treatment-emergent nausea following BMT with or without concomitant use of Zofran.